• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A New Safe Harbor - Turning Drug Rebates into Discounts in Medicare Part D.

作者信息

Gellad Walid F, Ennis Molly, Kuza Courtney C

机构信息

From the Division of General Internal Medicine, School of Medicine (W.F.G.), the Center for Pharmaceutical Policy and Prescribing (W.F.G., C.C.K.), and the Health Policy Institute, Schools of the Health Sciences (M.E.), University of Pittsburgh, and the Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System (W.F.G.) - all in Pittsburgh.

出版信息

N Engl J Med. 2019 May 2;380(18):1688-1690. doi: 10.1056/NEJMp1902692. Epub 2019 Apr 3.

DOI:10.1056/NEJMp1902692
PMID:30946552
Abstract
摘要

相似文献

1
A New Safe Harbor - Turning Drug Rebates into Discounts in Medicare Part D.一个新的安全港——将药品回扣转化为医疗保险D部分的折扣
N Engl J Med. 2019 May 2;380(18):1688-1690. doi: 10.1056/NEJMp1902692. Epub 2019 Apr 3.
2
Rebates-The Little-Known Factor Behind Increasing Drug List Prices.回扣——药品目录价格上涨背后鲜为人知的因素。
JAMA. 2020 Mar 3;323(9):812-813. doi: 10.1001/jama.2020.1208.
3
How insurers' bargaining power affects drug prices in Medicare Part D.保险公司的议价能力如何影响医疗保险D部分的药品价格。
Natl Bur Econ Res Bull Aging Health. 2009(4):1-2.
4
Pharmaceuticals and medical devices: Medicare Part D. Issue brief.药品和医疗器械：医疗保险D部分。问题简报。
Issue Brief Health Policy Track Serv. 2012 Dec 31:1-32.
5
Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.预计降低丙型肝炎治疗药物的建议零售价后，制造商和医疗机构收入的变化。
JAMA Netw Open. 2019 Jul 3;2(7):e196541. doi: 10.1001/jamanetworkopen.2019.6541.
6
Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.医疗保险D部分处方药价格回扣与患者自付费用及联邦支出的关联
JAMA Intern Med. 2017 Aug 1;177(8):1185-1188. doi: 10.1001/jamainternmed.2017.1885.
7
Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.处方药——标价、净价与处于中间环节的回扣
JAMA. 2019 Apr 23;321(16):1563-1564. doi: 10.1001/jama.2019.2445.
8
Policy Recommendations for Public Health Plans to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians.《美国医师学院关于遏制处方药费用不断攀升的政策建议：立场文件》。
Ann Intern Med. 2019 Dec 3;171(11):825-827. doi: 10.7326/M19-0013. Epub 2019 Nov 12.
9
Who benefits from drug discounts? Drugmakers, hospitals battle over indigent-care program.谁能从药品折扣中受益？制药商与医院就贫困护理项目展开争斗。
Mod Healthc. 2013 Jul 15;43(28):8-9.
10
CMS retreats on Part D rule intended to reduce drug costs and improve access.医疗保险和医疗补助服务中心（CMS）撤回了旨在降低药品成本并改善医保覆盖范围的D部分规则。
Mod Healthc. 2014 Mar 17;44(11):10.

引用本文的文献

1
How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan.制药公司与医疗保健部门之间的机构利益冲突如何变得腐败？以日本 Mie 大学临床麻醉学系与小野制药公司之间的奖学金捐赠为例。
Front Public Health. 2022 Jan 3;9:762637. doi: 10.3389/fpubh.2021.762637. eCollection 2021.
2
Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.品牌药价格变化与患者自付费用的相关性。
JAMA Netw Open. 2021 May 3;4(5):e218816. doi: 10.1001/jamanetworkopen.2021.8816.
3
Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.
医疗保险部分 D 和抗逆转录病毒治疗和暴露前预防的费用分担。
JAMA Netw Open. 2020 Apr 1;3(4):e202739. doi: 10.1001/jamanetworkopen.2020.2739.
4
Origins of the Crisis in Insulin Affordability and Practical Advice for Clinicians on Using Human Insulin.胰岛素可负担性危机的起源及临床医生使用人胰岛素的实用建议。
Curr Diab Rep. 2020 Jan 29;20(1):2. doi: 10.1007/s11892-020-1286-3.